Cyclosporine (Systemic)
majorRifampicin is the most potent known CYP3A4 inducer, reducing cyclosporine plasma levels by 50-90% within days, causing therapeutic failure and transplant rejection or immune-mediated disease flare.
Management: Avoid combination. If essential, increase cyclosporine dose 2-5 fold and monitor trough levels closely. Consider alternative antibiotic.
Ketoconazole (Systemic)
majorRifampicin induces CYP3A4 metabolism of ketoconazole, dramatically reducing ketoconazole levels. Ketoconazole inhibits rifampicin absorption. Bidirectional antagonism.
Management: Avoid combination — both drugs lose efficacy. Use alternative antifungal or alternative antimycobacterial.
Rifampicin induces CYP3A4, reducing itraconazole levels by 70-90%. Renders antifungal therapy ineffective.
Management: Do not combine. Choose one: treat mycobacterial infection OR fungal infection sequentially, not concurrently.
Rifampicin induces CYP3A4 and CYP2B6, dramatically increasing methadone metabolism and causing opioid withdrawal or loss of analgesia.
Management: Avoid combination. If unavoidable, increase methadone dose significantly and monitor pain scores closely.